Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Míreanna Comhchosúla

• Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
  le: McIntyre, Kristi, et al.
  Foilsithe: (2014)
• Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
  le: Lee Schwartzberg, et al.
  Foilsithe: (2019-06-01)
• Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
  le: Schwartzberg, Lee, et al.
  Foilsithe: (2019)
• Impact of prior anthracycline or taxane use on eribulin effectiveness as first-line treatment for metastatic breast cancer: results from two phase 2, multicenter, single-arm studies
  le: O’Shaughnessy, Joyce, et al.
  Foilsithe: (2015)
• Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
  le: Puhalla, Shannon, et al.
  Foilsithe: (2016)